Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arimidex Clear all
Completed Phase 1 Interventional

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

NCT00508586
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 25, 2026, 10:54 PM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00090974
View directory record Official record
Conditions
Breast Cancer
Interventions
quality-of-life assessment
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
224
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fairfield, California + 144 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 25, 2026, 10:54 PM EDT
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

NCT01783444
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Exemestane, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 2 Interventional

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891
View directory record Official record
Conditions
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Oana Danciu
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Endocrine Response in Women With Invasive Lobular Breast Cancer

NCT02206984
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen, Anastrozole, Fulvestrant
Drug
Lead sponsor
Priscilla McAuliffe
Other
Eligibility
Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Withdrawn Phase 2 Interventional

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

NCT00217659
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, goserelin acetate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
57
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

NCT04352777
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Abemaciclib, Fulvestrant, Aromatase Inhibitors
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

NCT00213148
View directory record Official record
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

NCT00309855
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone, Anastrazole, Dutasteride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

NCT04294225
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Anastrozole, Letrozole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Pulmonary Hypertension and Anastrozole Trial

NCT03229499
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Anastrozole, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

NCT00283608
View directory record Official record
Conditions
Breast Cancer
Interventions
Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration
Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2011 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer

NCT01080170
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

NCT00077025
View directory record Official record
Conditions
Breast Cancer
Interventions
Gefitinib, Anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 3 Interventional

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
View directory record Official record
Conditions
Low Grade Serous Ovarian Cancer
Interventions
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging

NCT05700006
View directory record Official record
Conditions
Breast Neoplasm Female, Arthralgia, Aging
Interventions
Aromatase inhibitor
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

NCT02942355
View directory record Official record
Conditions
Female Breast Carcinoma, Breast Cancer
Interventions
anastrozole, Palbociclib
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 3 Interventional

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
127
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031
View directory record Official record
Conditions
Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Akt Inhibitor MK2206, Anastrozole, Fulvestrant, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 25, 2026, 10:54 PM EDT